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TREATMENT EFFICACY MODEL
The treatment efficacy model used Monte Carlo methods to simulate low-density lipoprotein cholesterol (LDL-C) and blood pressure (BP) reductions realized by each participant following exposure to each treatment. The simulation proceeded as follows. Population mean efficacy parameters were randomly sampled for each treatment using 95% confidence intervals abstracted from meta-analyses. Using these estimates and their corresponding variances (described in this section), we fitted normal efficacy distributions for each treatment and randomly sampled a treatment effect (measured as a per- centage reduction in the risk factor) for each participant having LDL-C or BP values above target levels at baseline. We then calculated each person's resulting risk factor level and assessed whether the target had been reached. Treatment for patients who did not reach targets levels were then intensified with step 2 treatments. The simu lation continued until all patients' LDL-C level and BP were below target levels or until all treatments had been exhausted.
We simulated adverse events following exposure to each treatment using probabilities from our reference studies and then simulated discontinuation from each treatment conditional on whether a patient incurred an adverse event. Accounting for treatment discontinuation is important to ensure that the overall treatment-related harm is not overestimated. We constrained treatment effects to be homogeneous in magnitude for all drugs from a common class by forcing a constant response percentile for each class based on the response percentile of the first drug in each class, which was determined randomly. We ran data for patients through the simulation 500 times to estimate mean risk factor reductions and mean treatment-related disutilities for each patient overall and for individual treatment steps.
Estimates of between-patient variation in relative risk factor reductions were abstracted from individual statin trials and pooled. Variance estimates for BP treatments were reported on the absolute scale but not the relative scale. We were therefore forced to use information at the study level, from which we could derive estimates of relative BP reductions by dividing the study's mean efficacy estimate by the baseline risk factor level in the treat- We modeled back-titration rates rather than additional myalgia adverse effects for subjects titrating to higher doses of statins. c For the base case analysis we assumed that incremental disutilities were 0.001, 0.002, 0.003, and 0.004 for the first 4 drug classes used. In sensitivity analyses, each drug class was assigned a constant incremental disutility of 0.001.
d For patients proceeding to high-dose antihypertensives, back-titration occurred when they experienced 2 or more adverse events per class.
(REPRINTED) ARCH INTERN MED/ VOL 170 (NO. 12), JUNE 28, 2010 WWW.ARCHINTERNMED.COM E2 ment group. We used the between-study variability to derive our between-patient variability estimates. Because this ecological approach almost certainly underestimates the true between-patient variance, our base case assumed that the mean±1 SD in the between-patient efficacy was equivalent to the range in the between-study efficacy. In our sensitivity analysis, we made a very conservative assumption that the between-patient variance was equal to the between-study variance in order to establish a lower bound on the between-patient variance. The overall results were not sensitive to the variance parameters.
SENSITIVITY ANALYSES
We explored the sensitivity of a number of our assumptions in additional analyses. As mentioned in the previous section, we used a more conservative estimate of patient-level variation in treatment response. We also used a more generous estimate of the efficacy of combination therapy-assuming that a third and fourth antihypertensive class added had the same relative efficacy as a 2-drug combination. (Adding a second drug to monotherapy was associated with a 16% lower systolic efficacy and 35% lower diastolic efficacy compared with the corresponding monotherapy.) We then used a more conservative, constant incremental polypharmacy disutility (0.001 for each drug class added) rather than one that increased linearly as a function of the number of drug classes used. We then used parameter estimates more appropriate for typical practice settings where patients tend to be sicker and less adherent than in clinical trial settings. We inflated discontinuation rates by 5 and 10 percentage points and assumed that real-world adherence was 10% and 20% lower than that found in randomized controlled trials. Next, we substituted utilities that were 50% lower and then 50% higher than the base case values, and then varied the latter 3 sets of parameters simultaneously in such a way that was least favorable to a treat-to-target strategy. Finally, we reran our base case simulation without discounting future health benefits. Abbreviations: BP, blood pressure; LDL-C, low-density lipoprotein cholesterol; NA, not applicable; QALY, quality-adjusted life-years. a Includes highest discontinuation rate, lowest adherence, and highest treatment disutility.
